JAZZ
Jazz Pharmaceuticals PLC
NASDAQ: JAZZ · HEALTHCARE · BIOTECHNOLOGY
$245.80
+2.21% today
Updated 2026-09-11
Market cap
$15.58B
P/E ratio
16.43
P/S ratio
3.39x
EPS (TTM)
$14.61
Dividend yield
—
52W range
$124 – $266
Volume
0.9M
WallStSmart proprietary scores
72
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B5.0
Quality
C+8.0
Profitability
A8.7
Valuation
A4/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$289.45
+17.76%
12-Month target
—
—
Intrinsic (DCF)
$344.71
Margin of safety
+51.77%
7 Strong Buy11 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 20.40% — above average
+ Free cash flow $397.60M — positive
+ Revenue growth 15.50% QoQ
+ 51.77% below intrinsic value
Risks
- Altman Z 0.87 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.66B | $3.83B | $4.07B | $4.27B | $4.60B |
| Net income | $-224.06M | $414.83M | $560.12M | $-356.15M | $192.80M |
| EPS | — | — | — | — | $14.61 |
| Free cash flow | $773.78M | $1.07B | $1.35B | $1.15B | $397.60M |
| Profit margin | -6.12% | 10.82% | 13.77% | -8.35% | 20.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-08 | HENDERSON, MARY ELIZABETH | Sale | 1,412 | $243.03 |
| 2026-09-08 | HENDERSON, MARY ELIZABETH | Sale | 15 | $241.20 |
| 2026-09-08 | GALA, RENEE D | Sale | 2,000 | $243.03 |
Peer comparison
Smart narrative
Jazz Pharmaceuticals PLC trades at $245.80. representing a P/E of 16.43x trailing earnings. Our Smart Value Score of 72/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.87, it sits in the distress. TTM revenue stands at $4.60B. with profit margins at 20.40%. Our DCF model estimates intrinsic value at $344.71.
Frequently asked questions
What is Jazz Pharmaceuticals PLC's stock price?
Jazz Pharmaceuticals PLC (JAZZ) trades at $245.80, on a P/E of 16.4x and a P/S of 3.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Jazz Pharmaceuticals PLC overvalued?
Jazz Pharmaceuticals PLC carries a Smart Value Score of 72/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $344.71 versus the $245.80 price, a 51.8% margin of safety on a cash flow basis.
What is the price target of Jazz Pharmaceuticals PLC (JAZZ)?
The 12-month analyst consensus target is $289.45, about 17.8% above the current $245.80. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Jazz Pharmaceuticals PLC (JAZZ)?
Our DCF model estimates intrinsic value at $344.71, a +51.8% margin of safety versus today's $245.80. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Jazz Pharmaceuticals PLC's revenue?
Jazz Pharmaceuticals PLC's trailing twelve-month revenue is $4.60B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Jazz Pharmaceuticals PLC's Altman Z-Score is 0.87, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.39x
ROE19.59%
Beta0.36
50D MA$248.88
200D MA$205.51
Shares out0.06B
Float0.06B
Short ratio—
Avg volume0.9M
Performance
1 week-0.41%
1 month+0.34%
3 months+6.60%
YTD+44.59%
1 year+94.83%
3 years—
5 years—